Tokio Marine Asset Management Co. Ltd. Has $3.51 Million Stake in Stryker Co. (NYSE:SYK)

Tokio Marine Asset Management Co. Ltd. grew its stake in shares of Stryker Co. (NYSE:SYK) by 3.5% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 9,750 shares of the medical technology company’s stock after buying an additional 333 shares during the period. Tokio Marine Asset Management Co. Ltd.’s holdings in Stryker were worth $3,510,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Capital Planning LLC grew its holdings in shares of Stryker by 3.6% during the 4th quarter. Capital Planning LLC now owns 841 shares of the medical technology company’s stock worth $304,000 after purchasing an additional 29 shares in the last quarter. Alhambra Investment Management LLC lifted its position in Stryker by 1.5% in the fourth quarter. Alhambra Investment Management LLC now owns 1,997 shares of the medical technology company’s stock worth $719,000 after purchasing an additional 29 shares during the period. Concord Wealth Partners boosted its stake in Stryker by 2.2% during the fourth quarter. Concord Wealth Partners now owns 1,396 shares of the medical technology company’s stock worth $503,000 after buying an additional 30 shares in the last quarter. Avestar Capital LLC increased its holdings in Stryker by 1.1% in the 3rd quarter. Avestar Capital LLC now owns 2,948 shares of the medical technology company’s stock valued at $1,065,000 after buying an additional 31 shares during the period. Finally, Union Savings Bank lifted its holdings in shares of Stryker by 1.0% during the 4th quarter. Union Savings Bank now owns 3,162 shares of the medical technology company’s stock worth $1,138,000 after acquiring an additional 31 shares during the period. Institutional investors own 77.09% of the company’s stock.

Stryker Trading Up 0.1 %

Shares of SYK opened at $390.90 on Monday. The stock’s fifty day simple moving average is $376.68 and its 200-day simple moving average is $363.02. The firm has a market capitalization of $149.02 billion, a PE ratio of 50.37, a price-to-earnings-growth ratio of 2.68 and a beta of 0.95. Stryker Co. has a 12-month low of $314.93 and a 12-month high of $406.19. The company has a quick ratio of 1.22, a current ratio of 1.91 and a debt-to-equity ratio of 0.66.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.86%. During the same period last year, the firm posted $3.46 EPS. As a group, research analysts predict that Stryker Co. will post 13.53 earnings per share for the current year.

Stryker Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st were given a dividend of $0.84 per share. This is a boost from Stryker’s previous quarterly dividend of $0.80. The ex-dividend date was Tuesday, December 31st. This represents a $3.36 annualized dividend and a dividend yield of 0.86%. Stryker’s payout ratio is presently 43.30%.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on SYK. Canaccord Genuity Group upped their target price on shares of Stryker from $420.00 to $435.00 and gave the company a “buy” rating in a research note on Wednesday, January 29th. StockNews.com cut Stryker from a “buy” rating to a “hold” rating in a report on Thursday. Robert W. Baird boosted their price target on Stryker from $378.00 to $405.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. JPMorgan Chase & Co. increased their price objective on Stryker from $420.00 to $445.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 29th. Finally, Barclays boosted their target price on shares of Stryker from $402.00 to $418.00 and gave the company an “overweight” rating in a research note on Thursday, October 31st. Five analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $419.37.

Insider Transactions at Stryker

In related news, CEO Kevin Lobo sold 57,313 shares of the stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $368.70, for a total value of $21,131,303.10. Following the sale, the chief executive officer now directly owns 100,027 shares in the company, valued at $36,879,954.90. This trade represents a 36.43 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 5.90% of the stock is owned by corporate insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.